Salaffi F, et al. - This prospective study was sought to ascertain the dimension of adherence in rheumatoid arthritis (RA) patients receiving subcutaneously administered anti-tumor necrosis factor-α (anti-TNFα) agents and to estimate the impact of injection site pain and skin perceptions following subcutaneous administration of anti-TNFα drugs on patients’ adherence. Researchers included an inception cohort of individuals starting subcutaneously administered anti-TNFα treatment. They evaluated injection site pain perception through the Self-Injection Assessment Pain Questionnaire (SIAPQ), and adherence to treatment was determined by the Compliance Questionnaire for Rheumatology (CQR5). For 193 individuals, adherence data over a 12-month interval were available. Both demographic characteristics (age) and clinical factors (disease activity, comorbidity burden, and injection site pain and skin perception) affected adherence in RA individuals.